Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: CBD, Placebo; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bloomfield Township, Michigan

Conditions: Orthostatic Intolerance, Parkinson's Disease
Interventions: Midodrine; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 22 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke
Interventions: D-cycloserine, Placebo, HandMentor Pro; Drug · Other · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Rosacea
Interventions: Doxycycline, Placebo; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Hot Springs, Arkansas • San Diego, California • Evansville, Indiana + 7 more

Conditions: Overactive Bladder
Interventions: Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets, Placebo orally disintegrating tablets; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Healthy
Interventions: JNJ-26366821, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stress Fracture of Tibia or Fibula
Interventions: Teriparatide, Placebos; Drug
Lead sponsor: University of South Carolina; Other
Eligibility: Not listed
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Ulcerative Colitis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more

Conditions: Alzheimer's Disease
Interventions: Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 1,467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Atopic Asthma
Interventions: CURCUMIN, no intervention other than stopping study; Dietary Supplement · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Primary Hyperparathyroidism, Vitamin D Deficiency
Interventions: 10,000 IU Vitamin D3, Placebo, Vitamin D; Drug · Other · Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL747, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 94
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Beverly Hills, California • Chapel Hill, North Carolina

Conditions: Subjective Tinnitus
Interventions: Conventional sound generator (SG), Placebo sound generator (placebo SG), Standard of Care (SC), Directive Counseling (DC); Device · Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: Camp Pendleton, California • San Diego, California • Travis Air Force Base, California + 3 more

Conditions: Healthy Volunteers
Interventions: Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg; Drug
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Heart Failure, Diastolic Heart Failure
Interventions: KNO3, KCl; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Panic Disorder, Insomnia
Interventions: Placebo and Escitalopram, Ramelteon and Escitalopram; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Asthma
Interventions: Albuterol MDPI, Placebo, ProAir HFA inhaler; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions: Rozanolixizumab, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more

Conditions: Wound Heal, Scar, Scar, Hypertrophic, Keloid, Keloid Scar Following Surgery, Surgical Incision
Interventions: Preoperative silicone ointment, Preoperative placebo ointment; Device · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions: pamidronate, saline; Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 4 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Delirium in Old Age
Interventions: Suvorexant 20 mg, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine

NMDA Receptors in Motor Learning in Humans

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma

Vitamin D Repletion in Primary Hyperparathyroidism

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Tinnitus Retraining Therapy Trial

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF

Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Preoperative Silicone Ointment and Wound Healing

Prevention of Post Operative Bone Loss in Children

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant